Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that the latest data from the ongoing Phase 1/2 clinical trial of SCIB1 ImmunoBody® (‘SCIB1’) in patients with Stage III/IV melanoma will be presented in a poster at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30-June 3, 2014.
SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. The trial is an open label, non-randomised study to determine the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electroporation device (TDS-IM, manufactured by Ichor Medical Systems, USA). The study will also assess immune effects and anti-tumour activity in patients with melanoma.
An earlier submitted abstract of the poster can be accessed through the ASCO website at: http://abstracts2.asco.org/.
The title, timing and location of the poster presentation is as follows:
| Abstract: |
3061 |
| Title: |
Phase I trial of ImmunoBody in Melanoma patients |
| Presenter: |
Prof Poulam Patel |
| Session: |
Developmental Therapeutics - Immunotherapy |
| Day / Date: |
Sunday 1 June, 2014 |
| Session Time: |
8:00 am to 11:45 am |
| Location: |
S Hall A2 |
For Further Information:
| Dr Richard Goodfellow, Joint CEO |
Scancell Holdings Plc |
+ 44 (0) 20 3727 1000 |
| Professor Lindy Durrant, Joint CEO |
Scancell Holdings Plc |
|
| Camilla Hume/Stephen Keys |
Cenkos Securities plc |
+ 44 (0) 20 7397 8900 |
| Mo Noonan/Simon Conway |
FTI Consulting |
+ 44 (0) 20 3727 1000 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.